PALB2 and neoplasm: They further recommend testing for specific gene fusions, RAS/RAS driver mutations, homologous repair (BRCA1, BRCA2, PALB2) and mismatch repair mutations (MLH1, MSH2, MSH6, PMS2), as well as tumor microsatellite instability and tumor mutational burden.